
AI can streamline biosimilar adoption by simplifying prescribing decisions and reducing costs.

AI can streamline biosimilar adoption by simplifying prescribing decisions and reducing costs.

Gaps in education about biosimilars, particularly among pharmacists, patients, and prescribers, are a significant barrier to wider adoption.